# A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

> **NCT03683186** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **United Therapeutics** · enrollment: 1000 (estimated)

## Conditions studied

- PAH
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Hypertension
- Connective Tissue Diseases
- Familial Primary Pulmonary Hypertension
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension, Pulmonary
- Lung Diseases
- Respiratory Tract Disease

## Interventions

- **DRUG:** Ralinepag

## Key facts

- **NCT ID:** NCT03683186
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2019-09-23
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03683186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03683186, "A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03683186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*